Welcome to our dedicated page for Protara Therapeutics news (Ticker: TARA), a resource for investors and traders seeking the latest updates and insights on Protara Therapeutics stock.
Protara Therapeutics, Inc. (symbol: TARA) is a clinical-stage biopharmaceutical company specializing in identifying and advancing transformative therapies for individuals afflicted with rare and specialty diseases. Headquartered in New York, New York, the company’s mission is to discover, develop, and deliver breakthrough treatments for patients who have limited therapeutic options.
Protara’s leading program is TARA-002, an investigational cell therapy designed for the treatment of lymphatic malformations (LMs), a condition characterized by fluid-filled cysts. In a significant advancement for the company, TARA-002 has been granted the Rare Pediatric Disease designation by the U.S. Food and Drug Administration (FDA), spotlighting its potential impact on pediatric patients.
Another key asset in Protara’s pipeline is the development of intravenous (IV) choline chloride, a phospholipid substrate replacement therapy aimed at treating Intestinal Failure-Associated Liver Disease (IFALD). This investigational therapy underscores the company's commitment to addressing critical needs in the realm of pediatric and adult rare diseases.
The company's history dates back to its former identity as Artara Therapeutics, Inc. The name change to Protara Therapeutics, Inc. occurred in May 2020, reflecting a refreshed vision and strategic direction.
Protara’s forward-looking strategies are built upon solid research and development foundations, extensive clinical trial engagements, and meaningful partnerships. With recent financial updates, the company has ensured that its cash reserves, bolstered by anticipated net proceeds, can sustain its strategic plans into 2026. This financial planning provides a stable runway for Protara to continue its pioneering work and achieve significant milestones.
The company is actively involved in various clinical trials and regulatory interactions, aiming to bring its innovative therapies to market. Protara’s operational transparency and forward-looking statements indicate a robust business strategy focused on long-term growth and patient success.
For the latest updates on Protara Therapeutics, including performance, events, and developments, visit Protara Therapeutics or contact their offices directly at Justine O'Malley, Justine.OMalley@protaratx.com, 646-817-2836.
FAQ
What is the current stock price of Protara Therapeutics (TARA)?
What is the market cap of Protara Therapeutics (TARA)?
What is Protara Therapeutics, Inc. known for?
Where is Protara Therapeutics, Inc. headquartered?
What is TARA-002?
What is IV choline chloride?
When did Protara Therapeutics, Inc. change its name?
What recent designation has TARA-002 received from the FDA?
How long is Protara's financial runway expected to last?
Who can I contact for more information about Protara Therapeutics?
What is the primary focus of Protara's business strategy?
Does Protara engage in clinical trials?
